Topic: familial hyperch
Our latest Back to Basics is a wallchart highlighting key features about familial hypercholesterolaemia with links to other useful information.
Raised blood cholesterol is a major risk factor in developing coronary heart disease and other cardiovascular diseases. Effective and well-tolerated lipid-lowering treatment improves outcomes for patients with elevated cholesterol, especially those with familial hypercholesterolaemia.
Familial hypercholesterolaemia (FH) is a common monogenetic condition that causes high levels of cholesterol in the blood, resulting in an increased risk of heart disease at an early age. FH affects around one in every 270 people. That means that in England around 160,000 adults and 40,000 children under 18 years are likely to have FH, though only around 3,000 have been diagnosed by DNA testing. This article discusses the new implementation guide, which is designed to improve the identification and treatment of people with FH.
The updated NICE clinical guideline (CG71) on the identification and management of familial hypercholesterolaemia (FH) recommends that those at risk of FH should be offered DNA tests to confirm they have the condition. Previously, LDL-C levels have been used but they are not always accurate.